A number of European countries (including Ireland, France, the Netherlands, Sweden and the United Kingdom) indicate an increase seen during 2022, particularly since September 2022, in the number of cases of invasive Group A Streptococcus (iGAS) disease among children less than ten years of age.
Fanny Chereau, EPIET fellow from cohort 2016, was deployed with GOARN (Global Outbreak Alert and Response Network) to support the response to the plague outbreak in Madagascar, on October 2017.
Since 23 August 2017 there is an ongoing epidemic of plague in Madagascar. As of 20 October 2017 WHO has reported 1 365 cases and 106 deaths leading to 8 % case fatality. Nine hundred and fifteen (67%) cases are pneumonic plague cases. The high proportion of pneumonic plague among cases is of concern, indicating that droplet transmission is a driver of the spread of plague in Madagascar beyond the areas that have been considered as endemic for bubonic plague to date. In the last weeks, the number of new confirmed cases seem to be plateauing, indicating that the outbreak is gradually being controlled.
The study compares the incidence and serotype distribution of invasive pneumococcal disease (IPD) for pneumococcal meningitis and non-meningitis IPD in children from 2007 to 2010 with reference to the pre-vaccination period from 1997 to 2001 in Germany.
The authors describe the epidemiology of invasive Hib and nontype b H. influenzae infections in children <15 years of age in the United Kingdom from 1994 until 2008, and show that the resurgence in Hib disease during the years 1999-2003 did not affect the epidemiology of invasive nontype b H. influenzae disease in children, which provides further support against serotype replacement.
The authors present an appraisal of the pneumococcal epidemiological situation in 11 Central European countries. Data are based on study findings presented at the 12th Central European Vaccine Advisory Group (CEVAG) meeting, held on 21–22 May 2010 in Sofia, Bulgaria, and a literature review of the PubMed database.
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.